Kenvue Inc. (NYSE:KVUE) is Mayar Capital Ltd.’s 6th Largest Position

Mayar Capital Ltd. trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 11.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 265,816 shares of the company’s stock after selling 35,338 shares during the period. Kenvue accounts for 7.4% of Mayar Capital Ltd.’s portfolio, making the stock its 6th largest position. Mayar Capital Ltd.’s holdings in Kenvue were worth $5,675,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Alerus Financial NA grew its holdings in Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after purchasing an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC lifted its stake in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after acquiring an additional 500 shares during the period. Principle Wealth Partners LLC increased its stake in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after acquiring an additional 500 shares during the period. White Pine Capital LLC grew its position in Kenvue by 1.0% during the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after purchasing an additional 542 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after acquiring an additional 568 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Kenvue stock opened at $23.46 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The stock has a fifty day moving average of $21.64 and a two-hundred day moving average of $22.33. The company has a market capitalization of $44.83 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

Several brokerages have commented on KVUE. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.